From the provided author metadata (8 papers, 64 total citations, h-index 3), Sanidas’s scientific footprint appears emerging rather than mature; the strongest way to judge would be full-text methods/results scrutiny of the listed works.
Author Review: Ioannis Sanidas
Evidence constraint: You provided only (i) bibliometric metadata and (ii) paper titles/IDs—not DOIs, abstracts, or full text. Therefore, I will not claim anything about the scientific findings, mechanisms, study design, or quantitative results of those papers.
Instead, I critically review scientific strength using only what can be grounded in your supplied metadata.
1) Bibliometric signals (from your provided data)
Provided metrics: h-index = 3, total citations = 64, paper count = 8.
These are suggestive of a researcher who has published and garnered attention, but not enough information is available here to evaluate biological insight depth, reproducibility, or rigor.
Figure A — Citation concentration (derived from provided totals)
Raw numbers used: total citations = 64, papers = 8 (average citations per paper = 8.0).
Figure B — How “h-index=3” relates to total citations (conceptual)
This figure does not reconstruct the citation distribution across papers; it only visualizes that h-index=3 is consistent with a set of ≥3 papers being relatively cited.
2) What can (and cannot) be inferred about scientific strength
Known from your data
- Output presence: you provided 8 paper titles/IDs associated with I. Sanidas.
- Impact signal (global): you provided 64 total citations and h-index 3.
- Research themes (very coarse): titles suggest involvement in cell-cycle/RB/CDK and cancer-related topics, but titles alone do not validate biological correctness, novelty, or methodological rigor.
Not knowable from your data (major missing pieces)
- Mechanistic validity: we cannot check whether interpretations follow the data.
- Methodological rigor: no details on controls, blinding, replication, statistical plans, or model assumptions.
- Reproducibility: no raw data links, code, or experimental details are supplied.
- Bias/selection: no information about whether results were selectively reported or whether negative results exist.
- Study types: titles may include clinical/genomic abstracts, but without the full text we cannot verify design quality (e.g., prospective vs retrospective, sample size, endpoints).
3) Critical assessment (skeptical, evidence-gated)
With only bibliometric metadata and paper titles, the best-supported evaluation is that the author’s research footprint is non-trivial but still developing (h-index 3; total citations 64 across 8 papers).
This is a low-resolution proxy for scientific quality; it can be inflated/deflated by field size, citation culture, review articles, conference abstracts, and uneven citation distribution.
Without methods/results, we cannot reliably separate biological insight from citation-driven visibility.
Counterpoints: early-career researchers often show modest h-index/citations despite strong rigor; conversely, citations can accrue even when work is later refined or corrected.
Therefore, the strongest next step is full-text, methods-focused verification of the listed papers.
4) Listed works (titles/IDs only)
The following entries were supplied as part of the author record. No DOI/full text was provided here, so I only restate titles/IDs.
| Paper ID |
Title |
| 013edb0fa91dc29213d5b23f7433bbc721261adb | Identification and inhibition of the Cyclin D Rb-docking interface that drives cell division |
| 53dc9be099320f748d0c9cdd2217e3e52614d14a | Abstract PS4-02-20: Clinical and genomic biomarkers of capivasertib response in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC) |
| dbf36bb3d1cfdb743fb0815aed1a49298fbc4a2f | Abstract PS2-11-28: Gdc-4198, a next-generation CDK4/2 inhibitor, induces durable cell cycle arrest and overcomes CDK2-driven adaptation to CDK4 inhibition |
| 4fda9367057c56e2fb7e18640cd5d9d8e40fe801 | Targeting CDK2 for cancer therapy |
| f9900b7f402a23a48886cadde2caa2235a93dd00 | Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer |
| 31bb69adf9ed40a0e45a4eb47be85f7d5d2ca07b | Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy. |
| 20179e036b351ae9dee26f785edf8ab951ec70c7 | A code of mono-phosphorylation modulates the function of RB. Sanidas et al. |
| f400040f117346a4c758e37e4a1d299b9461013e | Comparison of 1‐week vs. 2‐ or 4‐week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication |
5) What I would need to do a true “scientific strength” review
To evaluate rigor/innovation biologically, I need for each paper: DOI/full text or at least abstract+methods, sample sizes, model systems, endpoints, key figures, statistical approach, and whether data/code are available.
With that, I can critique: (i) causality vs correlation, (ii) controls/blinding, (iii) replication, (iv) mechanistic consistency, and (v) citation context.
Quick Answer
Long Answer
Hypothesis Graveyard
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
